Articles related to MYELODYSPLASTIC SYNDROMES
CPX-351 vs. FLAG-Ida Treatment for Patients with Adverse Karyotype AML/High-Risk MDS
Discover why CPX-351 extends relapse-free survival but does not significantly alter overall survival in younger AML/MDS patients, as revealed by the UK NCRI AML19 trial.
Hematology October 9th 2023
Luspatercept Superior to Epoetin Alfa in Certain Myelodysplastic Syndromes
Luspatercept demonstrated superiority over epoetin alfa in improving red blood cell (RBC) transfusion independence in transfusion-dependent patients with lower-risk myelodysplastic syndromes (LR-MDS) who have not previously received erythropoiesis-stimulating agents (ESAs). These findings are part of a study that was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting:
Hematology June 5th 2023
Nutrition-Related Challenges Common for Older Adults with AML, MDS
Nutritional challenges are common in older adults with acute leukemia (AML/MDS), and can have a significant impact on their quality of life and treatment outcomes. These challenges can be caused by a variety of factors, including the disease itself, its treatment, and the normal aging process. Some of the most common nutritional challenges in older adults with AML/MDS include appetite loss, weight loss, diarrhea, constipation, and mouth sores; physicians can provide nutritional interventions to help address these challenges and improve the quality of life for older adults with AML/MDS. These interventions may include nutrition counseling, meal planning, supplementation, and enteral nutrition.
Geriatrics May 16th 2023
Ipilimumab plus Decitabine for Patients with MDS or AML in Posttransplant or Transplant-naïve Settings
In patients with R/R MDS/AML, the combination ipilimumab + decitabine (IPI + DEC) therapy shows a favorable safety profile and significant therapeutic activity that doesn’t seem to require T cell-mediated alloreactivity. Potential transplant candidates may find that IPI + DEC therapy acts as a less strenuous transition to transplant. Future research is necessary to determine logical IPI-based treatment plans that can provide persistent responses without causing significant immune damage.
Hematology April 24th 2023
ESA Failure in Low-Risk MDS: ESA Failure Criteria and Emerging Options to Promote Transfusion Independence
Hematologist-oncologists, hematology-oncology NP/PAs, hematology-oncology nurses, and pharmacists should be better able to use criteria for erythroid-stimulating agent (ESA) failure to hasten the identification of patients with lower-risk myelodysplastic syndrome (MDS) refractory to ESA therapy, integrate safety and efficacy data on emerging therapeutic options into treatment planning for patients with lower-risk MDS after ESA failure, and integrate a multidisciplinary treatment approach after taking part in this CME activity.
Hematology February 21st 2023